Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
From ELCC 2023:
Liposomal irinotecan does not offer significantly better overall survival than topotecan for patients with small-cell lung cancer that has progressed during or after first-line platinum-based chemotherapy
From ELCC 2023:
APPLE and NORTHSTAR updates add to understanding of osimertinib use among patients with advanced EGFR-mutated non-small-cell lung cancer
From 2023 ASCO GU Cancers Symposium:
The KEYNOTE-057 trial has shown promising efficacy and safety of pembrolizumab monotherapy for BCG-unresponsive, papillary high-risk non-muscle-invasive bladder cancer
Receive a summary of latest published content every two weeks.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
